Dermata Therapeutics (DRMA) Earnings Date, Estimates & Call Transcripts $0.68 -0.01 (-0.88%) Closing price 07/18/2025 03:49 PM EasternExtended Trading$0.65 -0.03 (-3.84%) As of 07/18/2025 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Dermata Therapeutics Earnings Summary Dermata Therapeutics announced Q1 2025 earnings on May 14, 2025, reporting an EPS of -$0.45, which hit the consensus estimate of -$0.45. Dermata Therapeutics currently has a trailing EPS of -$16.41Q1 2025 Earnings ResourcesQ1 2025 Earnings ReportDRMA Upcoming EarningsDermata Therapeutics' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Upcoming Q2 Earnings DateAug. 6Before Market OpensEstimatedConsensus EPS (May. 14) -$0.45 Actual EPS (May. 14) -$0.45 Get Dermata Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dermata Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataDRMA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Dermata Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)--------5/14/2025Q1 2025-$0.45-$0.45--$0.45--8/7/2024--$3.79-$4.18 -$0.39-$4.18--5/15/2024Q1 2024--$7.05--$7.05--3/21/2024Q4 2023--$3.15--$0.21--11/9/2023Q3 2023--$8.10--$0.54--8/10/2023Q2 2023--$9.45--$0.63-- More Earnings Resources from MarketBeat Related Companies Reviva Pharmaceuticals Earnings Results Hoth Therapeutics Earnings Results Citius Pharmaceuticals Earnings Results Calidi Biotherapeutics Earnings Results DURECT Earnings Results Carisma Therapeutics Earnings Results Marker Therapeutics Earnings Results ProPhase Labs Earnings Results Rallybio Earnings Results CASI Pharmaceuticals Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report This page (NASDAQ:DRMA) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
